Aurobindo in-licenced chemotherapy induced neutropenia drug Ryzneuta gets USFDA nod

Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF), Ryzneuta, to treat chemotherapy-induced Neutropenia (CIN) in cancer patients. Ryzneuta is the first non-pegylated G-CSF approved by both the USFDA and China's National Medical Products Administration (NMPA). The drug was in-licensed by Aurobindo's subsidiary Acrotech Biopharma last year. Acrotech is preparing to commercialize Ryzneuta, with Aurobindo Pharma expecting more regulatory approvals in the near future.

from Science News - Times of India https://ift.tt/sjUeuJR
via